Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard RBCs Clear all
Completed Phase 3 Interventional Results available

Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)

NCT00627393
View directory record Official record
Conditions
Neutropenia, Infection
Interventions
Standard antimicrobial therapy, Granulocyte transfusions, G-CSF/dexamethasone, Apheresis machine
Drug · Biological · Device
Lead sponsor
Carelon Research
Other
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
13
States / cities
Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 19, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available

Age of Blood in Children in Pediatric Intensive Care Units

NCT01977547
View directory record Official record
Conditions
Anemia
Interventions
Short storage RBC age
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Days to 15 Years
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 19, 2026, 9:40 PM EDT
Withdrawn Early Phase 1 Interventional

Utilization of Donor Whole Blood for Blood Transfusion in Deceased Donor Liver Transplantation

NCT04383756
View directory record Official record
Conditions
Transfusion Related Complication, Liver Transplant
Interventions
Donor Blood, Banked Blood
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 19, 2026, 9:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Blood Warming in Preterm Infants to Decrease Hypothermia

NCT05170633
View directory record Official record
Conditions
Preterm Birth, Blood Transfusion Complication, Hypothermia
Interventions
Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)
Device
Lead sponsor
University of South Carolina
Other
Eligibility
24 Weeks to 32 Weeks
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 19, 2026, 9:40 PM EDT
Recruiting Not applicable Interventional

Bladder Cancer Screening Trial

NCT05646485
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Hematuria, Smoking Cessation
Interventions
Urinalysis
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 19, 2026, 9:40 PM EDT
Completed Not applicable Interventional

Combining Restrictive Guidelines and a NIRS SCORE to Decrease RBC Transfusions

NCT02535208
View directory record Official record
Conditions
Anemia of Prematurity (AOP)
Interventions
Restrictive transfusions based on SCOR assessment, Liberal transfusions
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 3 Days
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 19, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

NCT02907359
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Interventions
Guadecitabine, Treatment Choice
Drug · Other
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Duarte, California • Rancho Mirage, California • Fleming Island, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 19, 2026, 9:40 PM EDT
Terminated Phase 2 Interventional Results available

Control of Major Bleeding After Trauma Study

NCT01838863
View directory record Official record
Conditions
Trauma, Hemorrhagic Shock
Interventions
Type AB plasma, Crystalloid fluid (standard of care for resuscitation)
Biological · Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 19, 2026, 9:40 PM EDT
Active, not recruiting Not applicable Interventional

Trial of Indication-Based Transfusion of Red Blood Cells in ECMO

NCT05405426
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation, Red Blood Cell Transfusion, Organ Failure, Multiple
Interventions
Red blood cell transfusion
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Days to 6 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 19, 2026, 9:40 PM EDT
Active, not recruiting Phase 3 Interventional

Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)

NCT03040778
View directory record Official record
Conditions
Medication-related Osteonecrosis of the Jaw, Bisphosphonate-related Osteonecrosis of the Jaw, Avascular Necrosis
Interventions
Pentoxifylline, Placebo, Tocopherol
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Ann Arbor, Michigan • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 19, 2026, 9:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion

NCT03999229
View directory record Official record
Conditions
Transfusion Related Complication
Interventions
SNO, Normal Saline, Red Blood Cell
Drug
Lead sponsor
James Reynolds
Other
Eligibility
18 Years to 35 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 19, 2026, 9:40 PM EDT
Completed Phase 4 Interventional Results available

Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions

NCT02731157
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Rejuvesol, Blood transfusion
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 19, 2026, 9:40 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

NCT06439082
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crizanlizumab, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 9:40 PM EDT
Withdrawn Phase 1 Interventional

POOLED Red Blood Cells Prepared From Pooling 5 Leukoreduced, Irradiated RBC Units

NCT03056378
View directory record Official record
Conditions
Transfusion Reaction, Anemia
Interventions
Standard RBCs
Biological
Lead sponsor
New York Blood Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 19, 2026, 9:40 PM EDT
Completed Phase 3 Interventional Results available

Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

NCT04704869
View directory record Official record
Conditions
Trauma Injury
Interventions
Cryoprecipitate, Red Blood Cells, Plasma, Platelets, Whole Blood
Biological
Lead sponsor
Bryan Cotton
Other
Eligibility
16 Years and older
Enrollment
1,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 19, 2026, 9:40 PM EDT
Completed Not applicable Interventional

Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status

NCT02835937
View directory record Official record
Conditions
Red Blood Cell Transfusions, Anemia, Hematology, Oncology, Ambulatory Care
Interventions
No-Transfuse
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 19, 2026, 9:40 PM EDT
Completed No phase listed Observational

PICU Transfusion Study: Harmful Effects of Red Blood Cell Transfusions

NCT02087553
View directory record Official record
Conditions
Iron, Abnormal Blood Level
Interventions
Transfusion of red blood cells, Infusion of albumin/saline
Biological
Lead sponsor
Columbia University
Other
Eligibility
Up to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 19, 2026, 9:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fresh Versus Old Red Blood Cells for Transfusion

NCT01319552
View directory record Official record
Conditions
Iron, Abnormal Blood Level, Other Abnormal Blood Chemistry
Interventions
Fresh transfusion, Old transfusion
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 19, 2026, 9:40 PM EDT
Completed Not applicable Interventional Results available

Oral Iron for Erythropoietic Protoporphyrias

NCT02979249
View directory record Official record
Conditions
Erythropoietic Protoporphyria, EPP, X-linked Protoporphyria, XLP
Interventions
Oral Iron
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 19, 2026, 9:40 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1

NCT07015437
View directory record Official record
Conditions
Healthy Subjects
Interventions
INTERCEPT Blood System for RBCs, Infusion of autologous radiolabeled RBCs
Device · Other
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Cincinnati, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 9:40 PM EDT
Active, not recruiting Phase 2 Interventional

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT02570542
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, Autologous Stem Cell Transplantation
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Omaha, Nebraska • Basking Ridge, New Jersey • Middletown, New Jersey + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 19, 2026, 9:40 PM EDT
Completed Not applicable Interventional Results available

Microfragmented Adipose Tissue Versus Platelet-rich Plasma for Knee Osteoarthritis: a Randomized Comparative Trial

NCT04351087
View directory record Official record
Conditions
Osteoarthritis, Knee, Microfragmented Adipose Tissue, Platelet-Rich Plasma
Interventions
Platelet Rich Plasma
Device
Lead sponsor
Ohio State University
Other
Eligibility
25 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 19, 2026, 9:40 PM EDT
Completed Not applicable Interventional

Vascular Changes of Rotator Cuff Repair Augmented With a Whole Blood Fibrin Clot

NCT03577379
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Whole Blood Fibrin Clot
Other
Lead sponsor
Santa Barbara Cottage Hospital
Other
Eligibility
18 Years to 69 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 19, 2026, 9:40 PM EDT
Completed Not applicable Interventional Results available

Low-Cost Platelet-Rich Plasma for Hemarthropathy

NCT06543368
View directory record Official record
Conditions
Hemarthrosis, Hemophilia
Interventions
Intra articular PRP Injection
Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 19, 2026, 9:40 PM EDT